Evidence map›Paper›PMID 37854341›Full record

ArticleBiologics : targets & therapy2023

Serum LINC00152 and UCA1 in HCV-Induced Hepatocellular Carcinoma: Clinical Significance and Prognostic Value.

Somaia Shehab-Eldeen, Abdallah Essa, Eman Salah Arafat, Asmaa Shaaban Sleem, Amal Abdelrasoul Alhosary, Ehab Darwish, Ali Essa, Omar Ahmed Al-Omair, Emad Ali Al-Khoufi, Abdulrhman Khaled Al Abdulqader and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biologics : targets & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Epigenetic Mechanisms Involved in Hcv Infection and Human HCC.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Somaia Shehab-EldeenInternal Medicine Department, College of Medicine, King Faisal University, Al-Ahsa, Kingdom of Saudi Arabia.ORCID 0000-0003-1429-0363
Abdallah EssaInternal Medicine Department, College of Medicine, King Faisal University, Al-Ahsa, Kingdom of Saudi Arabia.ORCID 0000-0001-6542-8532
Eman Salah ArafatMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University, Shebin Elkom, Egypt.
Asmaa Shaaban SleemMedical Microbiology and Immunology Department, Faculty of Medicine, Menoufia University, Shebin Elkom, Egypt.
Amal Abdelrasoul AlhosaryClinical Pathology Department, Faculty of Medicine, Menoufia University, Shebin Elkom, Egypt.
Ehab DarwishTropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.ORCID 0000-0001-5063-2792
Ali EssaMedical Student, Faculty of Medicine, Menoufia University, Shebin Elkom, Egypt.
Omar Ahmed Al-OmairInternal Medicine Department, College of Medicine, King Faisal University, Al-Ahsa, Kingdom of Saudi Arabia.ORCID 0000-0002-8498-1621
Emad Ali Al-KhoufiInternal Medicine Department, College of Medicine, King Faisal University, Al-Ahsa, Kingdom of Saudi Arabia.
Abdulrhman Khaled Al AbdulqaderInternal Medicine Department, College of Medicine, King Faisal University, Al-Ahsa, Kingdom of Saudi Arabia.
Ali NadaHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Shebin Elkom, Egypt.
King Faisal University · SAMenoufia University · EGZagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite significant advancements in the molecular characterization of hepatocellular carcinoma (HCC), no oncogene addiction has been discovered. Long noncoding RNAs (lncRNAs) have a lot of promise as cancer biomarkers. LINC00152 and UCA1 have shown potential as diagnostic, prognostic, and therapeutic targets for human cancers. Aim: To investigate the diagnostic and prognostic potential of serum LINC00152 and UCA1 in hepatocellular carcinoma (HCC). Methods: The expression levels of LINC00152 and UCA1 in blood samples from 120 patients (60 with HCC, 60 with liver cirrhosis) and 40 healthy subjects were assessed using real-time qRT-PCR. Results: Serum LINC00152 and UCA1 expression were considerably higher in HCC patients compared to patients with liver cirrhosis and the healthy controls (p<0.001 and p<0.001 respectively). And their expressions in the liver cirrhosis group were significantly higher than in healthy controls. Both lncRNAs performed well in the ROC analysis, distinguishing HCC patients from patients with liver cirrhosis. Higher levels of LINC00152 expression were linked to lesions in both lobes of the liver (p=0.02), while higher levels of UCA1 expression were linked to vascular invasion and the late stage (p=0.01, p=0.03 respectively). The multivariate analysis showed that a high level of LINC00152 in the blood was an independent indicator of a bad outcome for HCC patients (HR=2.23, 95% CI= 1.30-5.29, p=0.03). Conclusion: Serum LINC00152 and UCA1 expression were upregulated in patients with HCC, suggesting their use as non-invasive biomarkers for HCC. Furthermore, LINC00152 has the potential to serve as a prognostic indicator.

Indexed as

hepatocellular carcinomaLINC00152mortalitypredictorUCA1

Identifiers

PMID37854341
PMCPMC10581015
OpenAlexW4387604938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.